Close Menu

NEW YORK – By analyzing circulating tumor DNA (ctDNA) samples after treatment, it may be possible to identify stage III colon cancer patients who are at increased risk of relapse and disease progression, new research suggests.

"Our study highlights the potential clinical utility of ctDNA to guide therapeutic decision-making," corresponding author Jeanne Tie, a medical oncologist and personalized oncology researcher specializing in colorectal cancer at the Walter and Eliza Hall Institute of Medical Research, and her colleagues wrote. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.